Butyrate inhibits the retinoic acid-induced differentiation of F9 teratocarcinoma stem cells.
F9 mouse teratocarcinoma stem cells differentiate into parietal endoderm cells in the presence of retinoic acid, dibutyryl cyclic AMP, and theophylline (RACT). When F9 cells are exposed to 2-5 mM sodium butyrate plus RACT, they fail to differentiate. Differentiation is assessed by induction of laminin and collagen IV mRNA, the synthesis of laminin, collagen IV and plasminogen activator proteins, and alterations in cell morphology. Butyrate inhibits differentiation only when added within 8 hr after retinoic acid addition. Thus an early event in retinoid action on F9 cells is butyrate-sensitive. The population doubling time and cell cycle distribution of F9 cells are not altered within the first 24 hr after butyrate addition, suggesting that butyrate does not inhibit differentiation by inhibition of growth or normal cycling. However, butyrate does inhibit histone deacetylation in F9 cells, and this could be the mechanism by which butyrate inhibits differentiation.
D000085:Acetates / Q000378:metabolism; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D002087:Butyrates / Q000494:pharmacology*; D020148:Butyric Acid; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D005434:Flow Cytometry; D051379:Mice; D010960:Plasminogen Activators / Q000032:analysis; D013724:Teratoma / Q000473:pathology*; D013806:Theophylline / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology*
D000085:Acetates; D002087:Butyrates; D020148:Butyric Acid; D014212:Tretinoin; D003994:Bucladesine; D013806:Theophylline; D010960:Plasminogen Activators